Pharmacokinetics
The PK parameters for abemaciclib and galunisertib in the safety lead‐in arm and for abemaciclib plus LY3023414 in Arm B were consistent with the PKs observed in single agent studies (Table Similarly, steady‐state exposures for abemaciclib, its metabolites, galunisertib, and LY3023414 (Figure 